Related Experiment Videos
Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients
Elisa Caggiu1, Kai Paulus2, Giuseppe Mameli1
1Department of Biomedical Sciences, Section of Microbiology and Virology, University of Sassari, Viale San Pietro 43b, 07100 Sassari, Italy.
Abstract:
Parkinson's disease is a neurodegenerative disorder and its etiology is unknown, numerous studies show how different environmental factors can influence the development of disease. miRNAs are involved in several pathologies and their dysregulation contribute to different pathologies, also in neurodegenerative such as Parkinson's disease, Alzheimer's disease, Huntington's disease and Amyotrophic lateral sclerosis. In this study, we profiled the expression of different candidate miRNAs: miR-155, miR-26a, miR-146a, and miR132, in PBMCs of L-dopa treated Parkinson patients and unaffected controls (HCs).We investigated the expression of miRNAs by RT-real time PCR, the results were subjected to statistical analysis. miRNA-155-5p was generally up-regulated in PD patients compared to HCs whereas miRNA-146a-5p was down-regulated in PD patients in comparison to HCs. It is interesting to point out that the expression of miR-155-5p was modified by levodopa treatment, in fact a down-regulation of miR-155-5p in PD patients with the highest dosage was observed. In conclusion, miRNA 155 could not only be a promising target for the anti-inflammatory therapy in PD but also a good candidate as a disease progression biomarker. The role of levodopa in modulating the levels of miRNA 155 requires further studies.
Insights
MicroRNAs (miRNAs) show altered expression in Parkinson's disease (PD) patients. MiR-155-5p, a potential biomarker, is modulated by levodopa treatment, suggesting therapeutic implications.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder with unknown etiology.
- MicroRNAs (miRNAs) are implicated in various pathologies, including neurodegenerative diseases like PD.
- Environmental factors are suggested to influence PD development.
Purpose of the Study:
- To profile the expression of candidate miRNAs (miR-155, miR-26a, miR-146a, miR132) in Parkinson's disease patients.
- To investigate the potential role of miRNAs as biomarkers and therapeutic targets in PD.
- To explore the effect of levodopa treatment on miRNA expression in PD patients.
Main Methods:
- Profiling of candidate miRNA expression using RT-real-time PCR.
- Analysis of miRNA expression in peripheral blood mononuclear cells (PBMCs) from PD patients and healthy controls (HCs).
- Statistical analysis of gene expression data.
Main Results:
- MiRNA-155-5p was generally up-regulated in PD patients compared to HCs.
- MiRNA-146a-5p was down-regulated in PD patients compared to HCs.
- Levodopa treatment modulated miR-155-5p expression, showing down-regulation at higher dosages.
Conclusions:
- MiRNA-155-5p is a potential biomarker for Parkinson's disease progression.
- MiRNA-155 presents a promising target for anti-inflammatory therapy in PD.
- Further research is needed to understand levodopa's role in modulating miRNA-155 levels.